Abstract:The discovery of CRISPR/Cas has revolutionized the field of genome editing. CRIPSR/Cas components are part of the bacterial immune system and are able to induce double-strand DNA breaks in the genome, which are resolved by endogenous DNA repair mechanisms. The most relevant of these are the error-prone nonhomologous end joining and homology directed repair pathways. The former can lead to gene knockout by introduction of insertions and deletions at the cut site, while the latter can be used for gene correction based on a provided repair template. In this Account, we focus on the delivery aspects of CRISPR/Cas for therapeutic applications in vivo. Safe and effective delivery of the CRISPR/Cas components into the nucleus of affected cells is essential for therapeutic gene editing. These components can be delivered in several formats, such as pDNA, viral vectors, or ribonuclear complexes. In the ideal case, the delivery system should address the current limitations of CRISPR gene editing, which are (1) lack of targeting specific tissues or cells, (2) the inability to enter cells, (3) activation of the immune system, and (4) off-target events. To circumvent most of these problems, initial therapeutic applications of CRISPR/Cas were performed on cells ex vivo via classical methods (e.g., microinjection or electroporation) and novel methods (e.g., TRIAMF and iTOP). Ideal candidates for such methods are, for example, hematopoietic cells, but not all tissue types are suited for ex vivo manipulation. For direct in vivo application, however, delivery systems are needed that can target the CRISPR/Cas components to specific tissues or cells in the human body, without causing immune activation or causing high frequencies of off-target effects. Viral systems have been used as a first resort to transduce cells in vivo. These systems suffer from problems related to packaging constraints, immunogenicity, and longevity of Cas expression, which favors off-target events. Viral vectors are as such not the best choice for direct in vivo delivery of CRISPR/Cas. Synthetic vectors can deliver nucleic acids as well, without the innate disadvantages of viral vectors. They can be classed into lipid, polymeric, and inorganic particles, all of which have been reported in the literature. The advantage of synthetic systems is that they can deliver the CRISPR/Cas system also as a preformed ribonucleoprotein complex. The transient nature of this approach favors low frequencies of off-target events and minimizes the window of immune activation. Moreover, from a pharmaceutical perspective, synthetic delivery systems are much easier to scale up for clinical use compared to viral vectors and can be chemically functionalized with ligands to obtain target cell specificity. The first preclinical results with lipid nanoparticles delivering CRISPR/Cas either as mRNA or ribonucleoproteins are very promising. The goal is translating these CRISPR/Cas therapeutics to a clinical setting as well. Taken together, these current trends seem to favor the use of sgRNA/Cas ribonucleoprotein complexes delivered in vivo by synthetic particles.

Non-viral strategies for delivering genome editing enzymes

Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Tailoring Non-Viral Delivery Vehicles for Transporting Genome-Editing Tools

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

Challenges in Crispr/Cas9 Delivery: Potential Roles of Nonviral Vectors

In Vivo Delivery Systems for Therapeutic Genome Editing.

Delivery technologies for genome editing

Engineered materials for in vivo delivery of genome-editing machinery

Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics

Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing.

Nano-vectors for CRISPR/Cas9-mediated genome editing

Non-viral and Viral Delivery Systems for CRISPR-Cas9 Technology in the Biomedical Field

Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing

Delivery of CRISPR/Cas9 for Therapeutic Genome Editing

Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy

Non-viral Nanocarriers for CRISPR-Cas9 Gene Editing System Delivery

Delivery of CRISPR/Cas9 by novel strategies for gene therapy.

Development of Delivery Strategies for CRISPR‐Cas9 Genome Editing